Zacks Reiterates Underperform Rating for Auxilium Pharmaceuticals (AUXL)
Auxilium Pharmaceuticals (NASDAQ:AUXL)‘s stock had its “underperform” rating reaffirmed by Zacks in a report issued on Wednesday. They currently have a $16.00 price target on the stock. Zacks‘s price objective would indicate a potential downside of 9.30% from the company’s current price.
Zacks’ analyst wrote, “Auxilium’s second quarter results missed both revenues and earnings estimates primarily due to lower Testim revenues. Loss of $0.54 per share was much wider than the Zacks Consensus Estimate of a loss of $0.45 per share. Revenues decreased 17.4% year over year to $83.0 million in the second quarter and fell short of the Zacks Consensus Estimate of $91 million. While the Actient deal should help strengthen the company’s urology franchise and reduce its dependence on Testim, we are concerned about the lack of patent protection for some of the key Actient products. Auxilium is now treating Testim as a mature product and hence the company is banking heavily on the successful commercialization of Xiaflex and Stendra. We currently maintain our Underperform recommendation. . “
AUXL has been the subject of a number of other recent research reports. Analysts at RBC Capital cut their price target on shares of Auxilium Pharmaceuticals from $32.00 to $28.00 in a research note on Friday, August 8th. They now have an “outperform” rating on the stock. Separately, analysts at Aegis cut their price target on shares of Auxilium Pharmaceuticals to $34.00 in a research note on Thursday, August 7th. They noted that the move was a valuation call. Finally, analysts at Aegis initiated coverage on shares of Auxilium Pharmaceuticals in a research note on Thursday, June 26th. They set a “buy” rating and a $37.00 price target on the stock. Four analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $26.14.
Auxilium Pharmaceuticals (NASDAQ:AUXL) traded down 1.87% during mid-day trading on Wednesday, hitting $17.31. The stock had a trading volume of 746,417 shares. Auxilium Pharmaceuticals has a 52-week low of $16.36 and a 52-week high of $32.89. The stock’s 50-day moving average is $19. and its 200-day moving average is $23.8. The company’s market cap is $869.9 million. Auxilium Pharmaceuticals also was the target of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 12,858,783 shares, a decline of 6.9% from the July 15th total of 13,809,803 shares. Currently, 25.9% of the shares of the company are short sold. Based on an average trading volume of 968,566 shares, the days-to-cover ratio is presently 13.3 days.
Auxilium Pharmaceuticals (NASDAQ:AUXL) last announced its earnings results on Thursday, August 7th. The company reported ($0.44) earnings per share for the quarter, missing the analysts’ consensus estimate of $1.64 by $2.08. The company had revenue of $83.00 million for the quarter, compared to the consensus estimate of $482.80 million. During the same quarter last year, the company posted $0.22 earnings per share. Auxilium Pharmaceuticals’s revenue was down 17.4% compared to the same quarter last year. On average, analysts predict that Auxilium Pharmaceuticals will post $-0.41 earnings per share for the current fiscal year.
Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.